COLORECTAL NEOPLASMS

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This study tests a new drug called JDQ443, which targets a specific cancer-driving mutation (KRAS G12C), in combination with other drugs (trametinib, ribociclib, or cetuximab). The trial enrolls about 74 people with advanced solid tumors (like lung or colorectal cancer) that have…

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile …

This phase 2 pilot study is testing whether giving two immunotherapy drugs, botensilimab and balstilimab, before surgery can shrink tumors in people with colorectal cancer. The trial includes 26 participants across three groups, with some receiving more doses and one group having…

This study compares the immunotherapy drug pembrolizumab with standard chemotherapy in about 100 Chinese patients whose advanced colorectal cancer has a specific genetic feature (MSI-H or dMMR). The goal is to see if pembrolizumab can slow cancer growth or improve survival better…

This study tests a drug called tisotumab vedotin, alone or with other cancer medicines, in people with advanced colorectal, lung, pancreatic, or head and neck cancers that have stopped responding to standard treatments. About 350 participants receive different dosing schedules to…

This study tests a new drug called E7386 combined with other cancer drugs in people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose and to see if the combination can shrink tumors. About 300 …

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This study tests three different eating plans to see which helps overweight adults at risk for colorectal cancer eat healthier and lose weight. About 240 participants will follow one of the plans for 12 months, with support from phone calls and a phone app. The goal is to find be…

This study tests whether taking two drugs, eflornithine and sulindac, together can lower the chance of new high-risk growths or a second colon cancer in people who have already had stage 0 to III colon or rectal cancer. About 350 participants who are cancer-free after surgery wil…

This study tests whether a personalized home exercise program can improve physical function and quality of life in people aged 75 and older with colorectal cancer who are having surgery. Participants receive weekly phone coaching on strength, balance, and breathing exercises from…

This study looks at 64 patients with colorectal cancer that spread to the liver and was surgically removed. Researchers are analyzing tumor samples to see how different immune cells and growth patterns relate to survival and cancer recurrence. The goal is to better understand why…

This study tests whether a two-week plant-based Mediterranean diet can change gut bacteria and reduce inflammation in people who have had colon polyps removed. Thirty participants will eat high-fiber meals delivered to their homes, and researchers will track changes in blood and …

This study tests whether a simple blood test that looks for tumor DNA can detect colorectal cancer coming back earlier than standard CT scans. About 359 people who had surgery for stage II or III colorectal cancer will be randomly assigned to either the blood test plus frequent P…